The Report Biologics Market Analysis By Source (Microbial,
Mammalian), By Products (Monoclonal Antibodies, Vaccines, Recombinant Proteins,
Antisense, RNAi), By Disease Category, By Manufacturing, & Segment
Forecasts, 2018 - 2025
The global biologics market is anticipated to reach
USD 399.5 billion by 2025, according to a new report by Grand View Research,
Inc. Introduction of targeted therapies coupled with rising adoption of patient
centric personalized medicine anticipated to fuel demand. Ever-increasing
understanding of the cell physiology and stress, as well as the factors
involved in protein production and heterologous gene expression have empowered
the use of different living factories.
These living factories
are the prokaryotic and eukaryotic cells. Enhancement of drug functionality
through achieving successful protein folding and post-translational
modifications is supportive for projected progress rate.
Moreover, rising
adoption of biopharmaceuticals over chemically synthesized molecules is
expected to propel revenue generation significantly. In addition to this,
presence of several metabolic disorders that can be treated through the use of
biologics is attributive to influence demand.
Combination of advanced
bioengineering technologies for biopharmaceutical production is expected to
boost progress in pharmaceutical industry. With recent advances in automation,
the selection process can be done through high throughput screening (HTS)
system for selection of viable clones.
Aforementioned method
enables robust production of biopharmaceutical products by obtaining
high-producing cell line. Advances with respect to upstream and downstream
processing would directly translate into the growth in revenue for this market
at a larger level.
However, development of
biosimilars is expected to restrain the biologics year on year growth to
certain extent. Although, the regulatory approval pathway for these products is
not framed yet some drug manufacturers are opting to invest in the development
of biobetters.
Access Research Report of Biologics
Market @ http://www.grandviewresearch.com/industry-analysis/biologics-market
Further key findings from the report suggest:
· Microbial expression systems dominated the
market with respect to biopharmaceutical manufacturing
· Presence of substantial number of products
manufactured through the use of microbial sources can be attributed for largest
share
· Higher usage of monoclonal antibodies for
the treatment of different diseases responsible for revenue generation
· Moreover, pipeline drugs in the phase of
development anticipated to bolster growth
· Significant development pertaining to
vaccines and increasing adoption anticipated to fuel progress
· Oncology dominated over a decade and is
expected to sustain its share over the forecast period.
· Introduction of novel biologics with high
efficacy coupled with the augmenting incidences of cancer is the vital impact
rendering factor.
· Substantial sales of biologics in the U.S.
can be attributed for the largest share of North American market.
· Established participants are implementing
the manufacture of complex moieties in-house, which pronounces for the larger
share of in-house manufacturing.
· Asia Pacific is projected to showcase
fastest growth in the coming years.
· Increasing penetration of the biologics in
the developing economies is expected to contribute in the projected growth.
· Moreover, the university based projects
implemented herein are attributive for the projected growth.
· Key players contributing in this market are
F Hoffman La Roche, Samsung Biologics, Celltrion, Pfizer Inc., Amgen, Novo
Nordisk A/S, Sanofi, Abbvie Inc., Merck & Co. Inc, Addgene, Johnson &
Johnson Services Inc., and Eli Lilly & Company.
· These participants are investing in the
hybrid business models through providing technology and service platforms.
· Such milestones and royalties from
partnered programs enables the cash flow generation which can be utilized in
proprietary R&D.
Grand View Research has
segmented the biologics market on the basis of source, product, manufacturing,
disease category, and region:
Biologics Source Outlook (Revenue, USD Billion, 2014 -
2025)
·
Microbial
·
Mammalian
·
Others
Biologics Product Outlook (Revenue, USD Billion, 2014 -
2025)
·
Monoclonal Antibodies
Biologics Manufacturing Outlook (Revenue, USD Billion,
2014 - 2025)
o
In-house
o
Outsourced
Biologics Disease Category Outlook (Revenue, USD Billion,
2014 - 2025)
·
Oncology
·
Infectious Diseases
·
Immunological Disorders
·
Cardiovascular Disorders
·
Hematological Disorders
·
Others
Biologics Regional Outlook (Revenue, USD Billion, 2014 -
2025)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East and Africa (MEA)
Access Press Release of Biologics Market@ https://www.grandviewresearch.com/press-release/global-biologics-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
